Labradimil

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameLabradimil
Drug Alias Name拉贝地米LabradimilumReceptormediated permeabiliser 7拉雷地米Lobradimil +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBradykinin B2 receptor agonists
TargetsBradykinin B2 receptor
Therapy Area/IndicationsCNS Embryonal TumorBrain NeoplasmsMedulloblastoma +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPuerto Rico +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAlkermes Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlkermes PlcNational Cancer InstituteAlkermes Inc
Active IndicationsN/A
Inactive IndicationsCNS Embryonal TumorBrain NeoplasmsMedulloblastoma +[6] 

Other Information

ATC CodeN/A
Related LinksKEGG